Search results
Showing 401 to 450 of 8117 results
Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.
International health technology assessment collaboration expands
The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada has welcomed two further HTA bodies.
Around 100,000 fewer colonoscopies expected to take place each year following updated NICE guidance
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Details and meeting dates of the antimicrobials evaluation committee
Information and benefits about shared decision making. Includes links to patient decision aids.
Public health advisory committees (PHACs) are the standing committees responsible for the development of our public health guidance. Come to a meeting
Find out what a NICE lay members does
You should run a mini competition for the following lots only: lot 2: print books lot 3: electronic books lot 4: print and electronic journals.
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
Kidney conditions: CKD and blood pressure when ACR 70 or more (IND264)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
This indicator covers the percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either: no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM246
Lipid disorders: FH assessment and diagnosis (new readings) (IND261)
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
This indicator covers the contractor establishing and maintaining a register of patients with stroke or transient ischaemic attack (TIA). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM243
This indicator covers the contractor establishing and maintaining a register of patients in need of palliative care or support. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM242
Bipolar, schizophrenia and other psychoses: register (IND257)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM241
Bipolar, schizophrenia and other psychoses: register (lithium therapy) (IND256)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses, and other patients on lithium therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM240
This indicator covers the contractor establishing and maintaining a register of patients with established hypertension. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM239
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over with heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM238
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over receiving drug treatment for epilepsy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM237
This indicator covers the contractor establishing and maintaining a register of patients diagnosed with dementia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM236
This indicator covers the contractor establishing and maintaining a register of patients with coronary heart disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM235
This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder are set to benefit from a new treatment to help the skin wounds heal faster.
People with an acute respiratory infection (ARI) could be monitored from their own homes using technology platforms that will feedback vital information on their condition to clinical staff, NICE has said in draft guidance.
Join our panel to give your expert advice on tools and resources developed to support NICE guidance.
Inflammatory arthritis is a collective term for a group of conditions, including rheumatoid arthritis (RA) and spondyloarthritis (SpA), that cause...
Our quality standards set out priority areas for quality improvement in health, public health and social care. They highlight areas with identified...
Using NICE guidance in social work: examples for principal social workers
A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by principal social workers.
Admission to hospital and delayed discharge can affect people's mental and physical wellbeing and make them increasingly dependent on support services
We support the involvement of people who use services, carers, members of the public and organisations who represent their interests across NICE. Our
How voluntary and community sector (VCS) organisations can help us develop guidance
Support for organisations who contribute to developing our guidance
Find out how we assess the value of digital health technologies and help developers build the evidence needed to achieve market access and improve lives.
These resources are for users in England only. Find out more about our eligibility criteria . If you work somewhere else in the UK, you can still...
Tailored content for our communities: Medicines and prescribing, general practice, social care, the public, library and knowledge services and local government.
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.
Information about transport layer security (TLS) 1.2 upgrade
Andy Tilden, interim CEO at Skills for Care May 2019 What this report reinforces is Skills for Care's view that a skilled and knowledgeable
NICE is a great place to work. You'll be working alongside talented, friendly people on services that have a real impact on health and social care in...
We design, build, deliver and maintain over 30 digital services. We also look after NICE's network infrastructure. It's a highly collaborative, agile
We want people from all walks of life to contribute to our work and share their experience, expertise and passion. We are committed to providing a...
Our staff really enjoy working with us, thanks to our great package of rewards and benefits. We offer flexible ways of working, which means a better
We support the physical and mental health and wellbeing of our staff in a number of ways. There's an employee assistance programme, mental health...
Artificial intelligence technologies to speed up contouring in radiotherapy treatment planning
Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers such as lung, prostate or colorectal, NICE has said in draft guidance.
Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies...